Evolus (EOLS) to Release Earnings on Wednesday

Evolus (NASDAQ:EOLS - Get Free Report) will release its earnings data after the market closes on Wednesday, November 6th. Analysts expect Evolus to post earnings of ($0.08) per share for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.

Evolus (NASDAQ:EOLS - Get Free Report) last posted its earnings results on Wednesday, July 31st. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.02). The firm had revenue of $66.91 million for the quarter, compared to the consensus estimate of $65.06 million. On average, analysts expect Evolus to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Evolus Stock Performance

Shares of NASDAQ EOLS traded down $0.37 during mid-day trading on Wednesday, reaching $16.32. 164,021 shares of the company were exchanged, compared to its average volume of 579,724. The company's 50-day simple moving average is $16.19 and its 200-day simple moving average is $13.63. The company has a quick ratio of 2.67, a current ratio of 2.92 and a debt-to-equity ratio of 6.26. The stock has a market capitalization of $1.02 billion, a P/E ratio of -15.90 and a beta of 1.31. Evolus has a twelve month low of $7.44 and a twelve month high of $17.82.

Insiders Place Their Bets

In other Evolus news, CFO Sandra Beaver sold 3,276 shares of the business's stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the sale, the chief financial officer now directly owns 148,502 shares of the company's stock, valued at $2,224,559.96. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the business's stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the transaction, the chief marketing officer now owns 82,375 shares in the company, valued at approximately $1,305,643.75. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Sandra Beaver sold 3,276 shares of the business's stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the transaction, the chief financial officer now owns 148,502 shares in the company, valued at $2,224,559.96. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 6.10% of the company's stock.

Analyst Ratings Changes

Several analysts have weighed in on EOLS shares. Barclays lifted their price objective on shares of Evolus from $16.00 to $20.00 and gave the stock an "overweight" rating in a research note on Friday, September 13th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Evolus in a research note on Monday, September 16th. HC Wainwright reiterated a "buy" rating and issued a $27.00 price objective on shares of Evolus in a research note on Thursday, October 3rd. Finally, Needham & Company LLC reissued a "buy" rating and issued a $22.00 target price on shares of Evolus in a report on Friday, September 13th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.